CIITA and neoplasm: Based on the above results and on the ground of our large preclinical studies on the effect of CIITA-mediated MHC-II expression in a variety of tumor histotypes of distinct MHC genetic background, we were strongly motivated to assess, in an experimental animal model, the OSCC murine cell line MOC2, whether a vaccination approach with CIITA-mediated, MHC-II-expressing OSCC tumor cells could similarly induce a protective immune response in vivo (56–58).